JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/46766 |
Resumo: | Copyright © 2021 Moura and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC BY). The use,distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use,distribution or reproduction is permitted which does not comply with these terms |
id |
RCAP_ca279d04bd4658660ba6cb88cd9c7708 |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/46766 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritisB cellsJAK inhibitorsJAK-STAT pathwayCytokinesRheumatoid arthritisCopyright © 2021 Moura and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC BY). The use,distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use,distribution or reproduction is permitted which does not comply with these termsRheumatoid arthritis (RA) is a chronic, systemic immune-mediated inflammatory disease that can lead to joint destruction, functional disability and substantial comorbidity due to the involvement of multiple organs and systems. B cells have several important roles in RA pathogenesis, namely through autoantibody production, antigen presentation, T cell activation, cytokine release and ectopic lymphoid neogenesis. The success of B cell depletion therapy with rituximab, a monoclonal antibody directed against CD20 expressed by B cells, has further supported B cell intervention in RA development. Despite the efficacy of synthetic and biologic disease modifying anti-rheumatic drugs (DMARDs) in the treatment of RA, few patients reach sustained remission and refractory disease is a concern that needs critical evaluation and close monitoring. Janus kinase (JAK) inhibitors or JAKi are a new class of oral medications recently approved for the treatment of RA. JAK inhibitors suppress the activity of one or more of the JAK family of tyrosine kinases, thus interfering with the JAK-Signal Transducer and Activator of Transcription (STAT) signaling pathway. To date, there are five JAK inhibitors (tofacitinib, baricitinib, upadacitinib, peficitinib and filgotinib) approved in the USA, Europe and/ or Japan for RA treatment. Evidence from the literature indicates that JAK inhibitors interfere with B cell functions. In this review, the main results obtained in clinical trials, pharmacokinetic, in vitro and in vivo studies concerning the effects of JAK inhibitors on B cell immune responses in RA are summarized.FrontiersRepositório da Universidade de LisboaMoura, RitaFonseca, João Eurico2021-03-10T12:17:24Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/46766engFront Med (Lausanne). 2021 Feb 5;7:607725.10.3389/fmed.2020.6077252296-858Xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:49:13Zoai:repositorio.ul.pt:10451/46766Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:58:50.724668Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis |
title |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis |
spellingShingle |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis Moura, Rita B cells JAK inhibitors JAK-STAT pathway Cytokines Rheumatoid arthritis |
title_short |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis |
title_full |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis |
title_fullStr |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis |
title_full_unstemmed |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis |
title_sort |
JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis |
author |
Moura, Rita |
author_facet |
Moura, Rita Fonseca, João Eurico |
author_role |
author |
author2 |
Fonseca, João Eurico |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Moura, Rita Fonseca, João Eurico |
dc.subject.por.fl_str_mv |
B cells JAK inhibitors JAK-STAT pathway Cytokines Rheumatoid arthritis |
topic |
B cells JAK inhibitors JAK-STAT pathway Cytokines Rheumatoid arthritis |
description |
Copyright © 2021 Moura and Fonseca. This is an open-access article distributed under the terms of the Creative Commons Attribution License(CC BY). The use,distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use,distribution or reproduction is permitted which does not comply with these terms |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-03-10T12:17:24Z 2021 2021-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/46766 |
url |
http://hdl.handle.net/10451/46766 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Front Med (Lausanne). 2021 Feb 5;7:607725. 10.3389/fmed.2020.607725 2296-858X |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers |
publisher.none.fl_str_mv |
Frontiers |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134534245023744 |